Abstract
High-risk neuroblastoma remains one of the deadliest childhood cancers. Identification of metabolic pathways that drive or maintain high-risk neuroblastoma may open new avenues of therapeutic interventions. Here, we report the isolation and propagation of neuroblastoma sphere-forming cells with self-renewal and differentiation potential from tumors of the TH-MYCN mouse, an animal model of high-risk neuroblastoma with MYCN amplification. Transcriptional profiling reveals that mouse neuroblastoma sphere-forming cells acquire a metabolic program characterized by transcriptional activation of the cholesterol and serine-glycine synthesis pathways, primarily as a result of increased expression of sterol regulatory element binding factors and Atf4, respectively. This metabolic reprogramming is recapitulated in high-risk human neuroblastomas and is prognostic for poor clinical outcome. Genetic and pharmacological inhibition of the metabolic program markedly decreases the growth and tumorigenicity of both mouse neuroblastoma sphere-forming cells and human neuroblastoma cell lines. These findings suggest a therapeutic strategy for targeting the metabolic program of high-risk neuroblastoma.
Original language | English (US) |
---|---|
Pages (from-to) | 609-623 |
Number of pages | 15 |
Journal | Cell Reports |
Volume | 17 |
Issue number | 2 |
DOIs | |
State | Published - Oct 4 2016 |
Keywords
- MYCN
- TH-MYCN mouse
- cancer metabolism
- cholesterol biosynthesis
- high-risk neuroblastoma
- mevalonate pathway
- neuroblastoma stem cells
- serine-glycine biosynthesis
- statin
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)